| Issue Date | Title | Author(s) |
| 2010-01-01 | Thin films of a dimeric ruthenium phthalocyanine complex on gold | Rawling, T; Austin, CE; Zareie, HM; McDonagh, AM |
| 2017-01-01 | A novel synthetic analogue of v-3 17,18-epoxyeicosatetraenoic acid activates TNF receptor-1/ ASK1/JNK signaling to promote apoptosis in human breast cancer cells | Dyari, HRE; Rawling, T; Chen, Y; Sudarmana, W; Bourget, K; Dwyer, JM; Allison, SE; Murray, M |
| 2012-07-15 | Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites | Ghassabian, S; Rawling, T; Zhou, F; Doddareddy, MR; Tattam, BN; Hibbs, DE; Edwards, RJ; Cui, PH; Murray, M |
| 2014-11-01 | Selective inhibition of human solute carrier transporters by multikinase inhibitors | Johnston, RA; Rawling, T; Chan, T; Zhou, F; Murray, M |
| 2019-03-01 | Aryl-urea fatty acids that activate the p38 MAP kinase and down-regulate multiple cyclins decrease the viability of MDA-MB-231 breast cancer cells | Al-Zubaidi, Y; Pazderka, C; Koolaji, N; Rahman, MK; Choucair, H; Umashankar, B; Bourget, K; Chen, Y; Rawling, T; Murray, M |
| 2018-10-13 | Nanoemulsion-enabled oral delivery of novel anticancer ω-3 fatty acid derivatives | Pereira, GG; Rawling, T; Pozzoli, M; Pazderka, C; Chen, Y; Dunstan, CR; Murray, M; Sonvico, F |
| 2019-11-01 | Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib | Murray, M; Gillani, TB; Rawling, T; Nair, PC |
| 2019-10-01 | Identification of an allosteric binding site on the human glycine transporter, GlyT2, for bioactive lipid analgesics | Mostyn, SN; Wilson, KA; Schumann-Gillett, A; Frangos, ZJ; Shimmon, S; Rawling, T; Ryan, RM; O’mara, ML; Vandenberg, RJ |
| 2013-01-01 | Anti-proliferative actions of N0-desmethylsorafenib in human breast cancer cells | Cui, PH; Rawling, T; Gillani, TB; Bourget, K; Wang, XS; Zhou, F; Murray, M |
| 2020 | Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and Their Application in Drug Discovery. | Pazderka, CW; Oliver, B; Murray, M; Rawling, T |
